Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Bryan Patrick McKibben

Matt Aaron Tschantz

Derek Cogan

Hui Yu

Zhidong Chen

Daniel Richard Marshall

Steven Richard Brunette

Craig Andrew Miller

Jennifer Burke

Michael David Lawlor

Rene Marc Lemieux

Michael Jason Burke

Yunlong Zhang

Donghong Amy Gao

Lee Fader

John Lord

Jin Mi Kim

Michael Balestra

Joerg Bentzien

Jennifer A Kowalski

Joshua Courtney Horan

Eugene R Hickey

Weimin Liu

Neil Moss

Todd Bosanac

Hossein Razavi

Zhaoming Xiong

Peter Allen Nemoto

Anil Kumar Padyana

Alexander Heim-Riether

Pingrong Liu

Maolin Yu

Xin Guo

Fariba Soleymanzadeh

Wang Mao

Eric T Larson

René Marc Lemieux

Antonio J M Barbosa

Yue Shen

Jianwen Cui

Kenneth Michael Meyers

Antonio J M Barbosa, Jr

Sabine Ruppel

Yang Yu

Elizabeth Spencer

Antonio Jose Del Moral Barbosa, Jr

Simon Suprenant

Ryan Michael Fryer

Kosea S Frederick

Rene' Marc Lemieux

Matthew A Cerny

Eric Thomas Larson

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R, R, R, R, Rand n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases

The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R&#x2014;, R&#x2014;, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Substituted benzamides as RIPK2 inhibitors

The present invention encompasses compounds of the formula (I) wherein the groups R, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Heteroaromatic compounds as BTK inhibitors

The present invention encompasses compounds of the formulas (I) & (II), wherein the groups A, L and Ar are defined as in claim, which are suitable for the treatment of diseases related to KCa3.1, process of making, pharmaceutical preparations which contain compounds and their methods of use. 

Fused thiazin-3-ones as KCA3.1 inhibitors

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein Cy, Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Aldosterone synthase inhibitors

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

[object Object]

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides

Disclosed are novel compounds of formula (I): wherein X, Y, R, Rand Rare as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Pyrimidine derivatives useful as inhibitors of PKC-theta

The invention comprises a class of derivatives of substituted benzylimidazoles of the formula (I) and methods for making the same. These compounds are useful for the treatment of inflammatory conditions. 

Substituted benzylimidazoles useful for the treatment of inflammatory diseases

Growing community of inventors

New Milford, CT, United States of America

Bryan Patrick McKibben